Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Argent Biopharma ( (AU:RGT) ) has shared an announcement.
Argent BioPharma has completed an operational restructuring, transferring its European manufacturing sites to third-party operators, resulting in annual savings of over USD $1 million. This strategic shift allows the company to focus on proprietary clinical development in neuroimmune therapeutic areas, enhancing its long-term value and independence. With regulatory approvals and initial purchase orders for its lead drug candidates CannEpil® and CogniCann® in Germany, Argent BioPharma is advancing its commercial strategy and commitment to effective neuroimmune therapies.
More about Argent Biopharma
Argent BioPharma Limited (ASX: RGT) is a clinical-stage biopharmaceutical company specializing in neuroimmunology and advanced nanomedicine. The company leverages its Neuro-Immune Modulatory (NIM) System to develop a robust pipeline of therapies targeting central nervous system disorders and immune-related conditions, including cannabinoid-based therapeutics.
YTD Price Performance: -20.83%
Average Trading Volume: 490
Technical Sentiment Signal: Buy
Current Market Cap: $6.77M
See more data about RGT stock on TipRanks’ Stock Analysis page.